nodes	percent_of_prediction	percent_of_DWPC	metapath
Baclofen—Coordination abnormal—Doxorubicin—liver cancer	0.0035	0.00355	CcSEcCtD
Baclofen—Skin disorder—Sorafenib—liver cancer	0.00348	0.00354	CcSEcCtD
Baclofen—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.00344	0.00349	CcSEcCtD
Baclofen—Vaginal inflammation—Doxorubicin—liver cancer	0.00344	0.00349	CcSEcCtD
Baclofen—Pulmonary embolism—Doxorubicin—liver cancer	0.00344	0.00349	CcSEcCtD
Baclofen—Anorexia—Sorafenib—liver cancer	0.00342	0.00347	CcSEcCtD
Baclofen—Dermatitis contact—Doxorubicin—liver cancer	0.0034	0.00345	CcSEcCtD
Baclofen—Coma—Epirubicin—liver cancer	0.0034	0.00345	CcSEcCtD
Baclofen—Bladder pain—Epirubicin—liver cancer	0.00336	0.00341	CcSEcCtD
Baclofen—Ibuprofen—PPARG—liver cancer	0.00335	0.727	CrCbGaD
Baclofen—Salivary hypersecretion—Doxorubicin—liver cancer	0.00334	0.00339	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00327	0.00332	CcSEcCtD
Baclofen—Hypertonia—Epirubicin—liver cancer	0.00326	0.00331	CcSEcCtD
Baclofen—Vaginal infection—Doxorubicin—liver cancer	0.00325	0.0033	CcSEcCtD
Baclofen—Abnormal vision—Epirubicin—liver cancer	0.00324	0.00329	CcSEcCtD
Baclofen—Sepsis—Epirubicin—liver cancer	0.00322	0.00327	CcSEcCtD
Baclofen—Mental disability—Epirubicin—liver cancer	0.00322	0.00327	CcSEcCtD
Baclofen—Dyspnoea—Sorafenib—liver cancer	0.0032	0.00325	CcSEcCtD
Baclofen—Dyspepsia—Sorafenib—liver cancer	0.00316	0.00321	CcSEcCtD
Baclofen—Coma—Doxorubicin—liver cancer	0.00314	0.00319	CcSEcCtD
Baclofen—Decreased appetite—Sorafenib—liver cancer	0.00312	0.00317	CcSEcCtD
Baclofen—Thrombophlebitis—Epirubicin—liver cancer	0.00312	0.00316	CcSEcCtD
Baclofen—Bladder pain—Doxorubicin—liver cancer	0.00311	0.00316	CcSEcCtD
Baclofen—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.0031	0.00315	CcSEcCtD
Baclofen—Gastrointestinal disorder—Sorafenib—liver cancer	0.0031	0.00314	CcSEcCtD
Baclofen—Fatigue—Sorafenib—liver cancer	0.00309	0.00314	CcSEcCtD
Baclofen—Hepatic function abnormal—Epirubicin—liver cancer	0.00309	0.00313	CcSEcCtD
Baclofen—Pain—Sorafenib—liver cancer	0.00307	0.00311	CcSEcCtD
Baclofen—Constipation—Sorafenib—liver cancer	0.00307	0.00311	CcSEcCtD
Baclofen—Hypertonia—Doxorubicin—liver cancer	0.00301	0.00306	CcSEcCtD
Baclofen—Abnormal vision—Doxorubicin—liver cancer	0.003	0.00304	CcSEcCtD
Baclofen—Mental disability—Doxorubicin—liver cancer	0.00298	0.00303	CcSEcCtD
Baclofen—Sepsis—Doxorubicin—liver cancer	0.00298	0.00303	CcSEcCtD
Baclofen—Gastrointestinal pain—Sorafenib—liver cancer	0.00293	0.00298	CcSEcCtD
Baclofen—Thrombophlebitis—Doxorubicin—liver cancer	0.00288	0.00293	CcSEcCtD
Baclofen—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00287	0.00291	CcSEcCtD
Baclofen—Hepatic function abnormal—Doxorubicin—liver cancer	0.00286	0.0029	CcSEcCtD
Baclofen—Urticaria—Sorafenib—liver cancer	0.00285	0.00289	CcSEcCtD
Baclofen—Abdominal pain—Sorafenib—liver cancer	0.00284	0.00288	CcSEcCtD
Baclofen—Body temperature increased—Sorafenib—liver cancer	0.00284	0.00288	CcSEcCtD
Baclofen—Lethargy—Epirubicin—liver cancer	0.00275	0.00279	CcSEcCtD
Baclofen—Cerebrovascular accident—Epirubicin—liver cancer	0.00275	0.00279	CcSEcCtD
Baclofen—Diplopia—Epirubicin—liver cancer	0.0027	0.00274	CcSEcCtD
Baclofen—Osteoarthritis—Epirubicin—liver cancer	0.0027	0.00274	CcSEcCtD
Baclofen—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.0027	0.00274	CcSEcCtD
Baclofen—Affect lability—Epirubicin—liver cancer	0.00266	0.0027	CcSEcCtD
Baclofen—Face oedema—Epirubicin—liver cancer	0.0026	0.00264	CcSEcCtD
Baclofen—Asthenia—Sorafenib—liver cancer	0.00257	0.00261	CcSEcCtD
Baclofen—Mood swings—Epirubicin—liver cancer	0.00256	0.00259	CcSEcCtD
Baclofen—Lethargy—Doxorubicin—liver cancer	0.00255	0.00259	CcSEcCtD
Baclofen—Cerebrovascular accident—Doxorubicin—liver cancer	0.00255	0.00259	CcSEcCtD
Baclofen—Pruritus—Sorafenib—liver cancer	0.00254	0.00258	CcSEcCtD
Baclofen—Ataxia—Epirubicin—liver cancer	0.00254	0.00257	CcSEcCtD
Baclofen—Dehydration—Epirubicin—liver cancer	0.00251	0.00255	CcSEcCtD
Baclofen—Osteoarthritis—Doxorubicin—liver cancer	0.0025	0.00253	CcSEcCtD
Baclofen—Diplopia—Doxorubicin—liver cancer	0.0025	0.00253	CcSEcCtD
Baclofen—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.0025	0.00253	CcSEcCtD
Baclofen—Orthostatic hypotension—Epirubicin—liver cancer	0.00246	0.0025	CcSEcCtD
Baclofen—Affect lability—Doxorubicin—liver cancer	0.00246	0.00249	CcSEcCtD
Baclofen—Diarrhoea—Sorafenib—liver cancer	0.00245	0.00249	CcSEcCtD
Baclofen—Breast disorder—Epirubicin—liver cancer	0.00244	0.00247	CcSEcCtD
Baclofen—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00243	0.00247	CcSEcCtD
Baclofen—Face oedema—Doxorubicin—liver cancer	0.00241	0.00245	CcSEcCtD
Baclofen—Muscular weakness—Epirubicin—liver cancer	0.00238	0.00242	CcSEcCtD
Baclofen—Dizziness—Sorafenib—liver cancer	0.00237	0.00241	CcSEcCtD
Baclofen—Mood swings—Doxorubicin—liver cancer	0.00236	0.0024	CcSEcCtD
Baclofen—Ataxia—Doxorubicin—liver cancer	0.00235	0.00238	CcSEcCtD
Baclofen—Dysphagia—Epirubicin—liver cancer	0.00233	0.00237	CcSEcCtD
Baclofen—Influenza—Epirubicin—liver cancer	0.00233	0.00237	CcSEcCtD
Baclofen—Dehydration—Doxorubicin—liver cancer	0.00232	0.00236	CcSEcCtD
Baclofen—Vomiting—Sorafenib—liver cancer	0.00228	0.00232	CcSEcCtD
Baclofen—Orthostatic hypotension—Doxorubicin—liver cancer	0.00228	0.00231	CcSEcCtD
Baclofen—Rash—Sorafenib—liver cancer	0.00226	0.0023	CcSEcCtD
Baclofen—Dermatitis—Sorafenib—liver cancer	0.00226	0.00229	CcSEcCtD
Baclofen—Breast disorder—Doxorubicin—liver cancer	0.00226	0.00229	CcSEcCtD
Baclofen—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00225	0.00228	CcSEcCtD
Baclofen—Headache—Sorafenib—liver cancer	0.00225	0.00228	CcSEcCtD
Baclofen—Muscular weakness—Doxorubicin—liver cancer	0.0022	0.00223	CcSEcCtD
Baclofen—Dysuria—Epirubicin—liver cancer	0.00218	0.00221	CcSEcCtD
Baclofen—Dysphagia—Doxorubicin—liver cancer	0.00216	0.00219	CcSEcCtD
Baclofen—Influenza—Doxorubicin—liver cancer	0.00216	0.00219	CcSEcCtD
Baclofen—Pollakiuria—Epirubicin—liver cancer	0.00215	0.00219	CcSEcCtD
Baclofen—Nausea—Sorafenib—liver cancer	0.00213	0.00216	CcSEcCtD
Baclofen—Weight increased—Epirubicin—liver cancer	0.00212	0.00215	CcSEcCtD
Baclofen—Weight decreased—Epirubicin—liver cancer	0.00211	0.00214	CcSEcCtD
Baclofen—Hyperglycaemia—Epirubicin—liver cancer	0.0021	0.00213	CcSEcCtD
Baclofen—Pneumonia—Epirubicin—liver cancer	0.00209	0.00212	CcSEcCtD
Baclofen—Drowsiness—Epirubicin—liver cancer	0.00208	0.00211	CcSEcCtD
Baclofen—Renal failure—Epirubicin—liver cancer	0.00204	0.00207	CcSEcCtD
Baclofen—Dysuria—Doxorubicin—liver cancer	0.00202	0.00205	CcSEcCtD
Baclofen—Sweating—Epirubicin—liver cancer	0.00199	0.00202	CcSEcCtD
Baclofen—Pollakiuria—Doxorubicin—liver cancer	0.00199	0.00202	CcSEcCtD
Baclofen—Haematuria—Epirubicin—liver cancer	0.00198	0.00201	CcSEcCtD
Baclofen—Hepatobiliary disease—Epirubicin—liver cancer	0.00197	0.002	CcSEcCtD
Baclofen—Weight increased—Doxorubicin—liver cancer	0.00196	0.00199	CcSEcCtD
Baclofen—Weight decreased—Doxorubicin—liver cancer	0.00195	0.00198	CcSEcCtD
Baclofen—Hyperglycaemia—Doxorubicin—liver cancer	0.00195	0.00198	CcSEcCtD
Baclofen—Pneumonia—Doxorubicin—liver cancer	0.00193	0.00196	CcSEcCtD
Baclofen—Drowsiness—Doxorubicin—liver cancer	0.00192	0.00195	CcSEcCtD
Baclofen—Bradycardia—Epirubicin—liver cancer	0.0019	0.00193	CcSEcCtD
Baclofen—Renal failure—Doxorubicin—liver cancer	0.00189	0.00192	CcSEcCtD
Baclofen—Rhinitis—Epirubicin—liver cancer	0.00187	0.0019	CcSEcCtD
Baclofen—Hypoaesthesia—Epirubicin—liver cancer	0.00186	0.00188	CcSEcCtD
Baclofen—Sweating—Doxorubicin—liver cancer	0.00184	0.00187	CcSEcCtD
Baclofen—Urinary tract disorder—Epirubicin—liver cancer	0.00184	0.00187	CcSEcCtD
Baclofen—Oedema peripheral—Epirubicin—liver cancer	0.00184	0.00187	CcSEcCtD
Baclofen—Haematuria—Doxorubicin—liver cancer	0.00183	0.00186	CcSEcCtD
Baclofen—Connective tissue disorder—Epirubicin—liver cancer	0.00183	0.00186	CcSEcCtD
Baclofen—Urethral disorder—Epirubicin—liver cancer	0.00183	0.00186	CcSEcCtD
Baclofen—Hepatobiliary disease—Doxorubicin—liver cancer	0.00182	0.00185	CcSEcCtD
Baclofen—Visual impairment—Epirubicin—liver cancer	0.0018	0.00183	CcSEcCtD
Baclofen—Bradycardia—Doxorubicin—liver cancer	0.00176	0.00178	CcSEcCtD
Baclofen—Eye disorder—Epirubicin—liver cancer	0.00174	0.00177	CcSEcCtD
Baclofen—Tinnitus—Epirubicin—liver cancer	0.00174	0.00177	CcSEcCtD
Baclofen—Cardiac disorder—Epirubicin—liver cancer	0.00173	0.00176	CcSEcCtD
Baclofen—Flushing—Epirubicin—liver cancer	0.00173	0.00176	CcSEcCtD
Baclofen—Rhinitis—Doxorubicin—liver cancer	0.00173	0.00176	CcSEcCtD
Baclofen—Hypoaesthesia—Doxorubicin—liver cancer	0.00172	0.00174	CcSEcCtD
Baclofen—Urinary tract disorder—Doxorubicin—liver cancer	0.00171	0.00173	CcSEcCtD
Baclofen—Oedema peripheral—Doxorubicin—liver cancer	0.0017	0.00173	CcSEcCtD
Baclofen—Connective tissue disorder—Doxorubicin—liver cancer	0.0017	0.00172	CcSEcCtD
Baclofen—Angiopathy—Epirubicin—liver cancer	0.00169	0.00172	CcSEcCtD
Baclofen—Urethral disorder—Doxorubicin—liver cancer	0.00169	0.00172	CcSEcCtD
Baclofen—Mediastinal disorder—Epirubicin—liver cancer	0.00168	0.00171	CcSEcCtD
Baclofen—Chills—Epirubicin—liver cancer	0.00167	0.0017	CcSEcCtD
Baclofen—Arrhythmia—Epirubicin—liver cancer	0.00167	0.00169	CcSEcCtD
Baclofen—Visual impairment—Doxorubicin—liver cancer	0.00166	0.00169	CcSEcCtD
Baclofen—Alopecia—Epirubicin—liver cancer	0.00165	0.00167	CcSEcCtD
Baclofen—Mental disorder—Epirubicin—liver cancer	0.00163	0.00166	CcSEcCtD
Baclofen—Malnutrition—Epirubicin—liver cancer	0.00162	0.00165	CcSEcCtD
Baclofen—Eye disorder—Doxorubicin—liver cancer	0.00161	0.00164	CcSEcCtD
Baclofen—Tinnitus—Doxorubicin—liver cancer	0.00161	0.00163	CcSEcCtD
Baclofen—Flushing—Doxorubicin—liver cancer	0.0016	0.00163	CcSEcCtD
Baclofen—Cardiac disorder—Doxorubicin—liver cancer	0.0016	0.00163	CcSEcCtD
Baclofen—Flatulence—Epirubicin—liver cancer	0.0016	0.00162	CcSEcCtD
Baclofen—Dysgeusia—Epirubicin—liver cancer	0.00159	0.00161	CcSEcCtD
Baclofen—Back pain—Epirubicin—liver cancer	0.00157	0.0016	CcSEcCtD
Baclofen—Angiopathy—Doxorubicin—liver cancer	0.00157	0.00159	CcSEcCtD
Baclofen—Mediastinal disorder—Doxorubicin—liver cancer	0.00156	0.00158	CcSEcCtD
Baclofen—Chills—Doxorubicin—liver cancer	0.00155	0.00157	CcSEcCtD
Baclofen—Arrhythmia—Doxorubicin—liver cancer	0.00154	0.00157	CcSEcCtD
Baclofen—Vision blurred—Epirubicin—liver cancer	0.00153	0.00155	CcSEcCtD
Baclofen—Alopecia—Doxorubicin—liver cancer	0.00153	0.00155	CcSEcCtD
Baclofen—Mental disorder—Doxorubicin—liver cancer	0.00151	0.00154	CcSEcCtD
Baclofen—Ill-defined disorder—Epirubicin—liver cancer	0.00151	0.00153	CcSEcCtD
Baclofen—Malnutrition—Doxorubicin—liver cancer	0.0015	0.00153	CcSEcCtD
Baclofen—Anaemia—Epirubicin—liver cancer	0.0015	0.00152	CcSEcCtD
Baclofen—Agitation—Epirubicin—liver cancer	0.00149	0.00152	CcSEcCtD
Baclofen—Flatulence—Doxorubicin—liver cancer	0.00148	0.0015	CcSEcCtD
Baclofen—Dysgeusia—Doxorubicin—liver cancer	0.00147	0.00149	CcSEcCtD
Baclofen—Malaise—Epirubicin—liver cancer	0.00147	0.00149	CcSEcCtD
Baclofen—Vertigo—Epirubicin—liver cancer	0.00146	0.00148	CcSEcCtD
Baclofen—Syncope—Epirubicin—liver cancer	0.00146	0.00148	CcSEcCtD
Baclofen—Back pain—Doxorubicin—liver cancer	0.00145	0.00148	CcSEcCtD
Baclofen—Palpitations—Epirubicin—liver cancer	0.00144	0.00146	CcSEcCtD
Baclofen—Loss of consciousness—Epirubicin—liver cancer	0.00143	0.00145	CcSEcCtD
Baclofen—Vision blurred—Doxorubicin—liver cancer	0.00142	0.00144	CcSEcCtD
Baclofen—Convulsion—Epirubicin—liver cancer	0.00141	0.00143	CcSEcCtD
Baclofen—Hypertension—Epirubicin—liver cancer	0.0014	0.00142	CcSEcCtD
Baclofen—Ill-defined disorder—Doxorubicin—liver cancer	0.00139	0.00142	CcSEcCtD
Baclofen—Anaemia—Doxorubicin—liver cancer	0.00139	0.00141	CcSEcCtD
Baclofen—Chest pain—Epirubicin—liver cancer	0.00138	0.0014	CcSEcCtD
Baclofen—Myalgia—Epirubicin—liver cancer	0.00138	0.0014	CcSEcCtD
Baclofen—Agitation—Doxorubicin—liver cancer	0.00138	0.0014	CcSEcCtD
Baclofen—Anxiety—Epirubicin—liver cancer	0.00138	0.0014	CcSEcCtD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00137	0.00139	CcSEcCtD
Baclofen—Discomfort—Epirubicin—liver cancer	0.00137	0.00139	CcSEcCtD
Baclofen—Malaise—Doxorubicin—liver cancer	0.00136	0.00138	CcSEcCtD
Baclofen—Dry mouth—Epirubicin—liver cancer	0.00135	0.00137	CcSEcCtD
Baclofen—Vertigo—Doxorubicin—liver cancer	0.00135	0.00137	CcSEcCtD
Baclofen—Syncope—Doxorubicin—liver cancer	0.00135	0.00137	CcSEcCtD
Baclofen—Confusional state—Epirubicin—liver cancer	0.00134	0.00136	CcSEcCtD
Baclofen—Palpitations—Doxorubicin—liver cancer	0.00133	0.00135	CcSEcCtD
Baclofen—Oedema—Epirubicin—liver cancer	0.00133	0.00135	CcSEcCtD
Baclofen—Loss of consciousness—Doxorubicin—liver cancer	0.00132	0.00134	CcSEcCtD
Baclofen—Infection—Epirubicin—liver cancer	0.00132	0.00134	CcSEcCtD
Baclofen—Shock—Epirubicin—liver cancer	0.0013	0.00132	CcSEcCtD
Baclofen—Convulsion—Doxorubicin—liver cancer	0.0013	0.00132	CcSEcCtD
Baclofen—Nervous system disorder—Epirubicin—liver cancer	0.0013	0.00132	CcSEcCtD
Baclofen—Hypertension—Doxorubicin—liver cancer	0.0013	0.00132	CcSEcCtD
Baclofen—Tachycardia—Epirubicin—liver cancer	0.00129	0.00131	CcSEcCtD
Baclofen—Skin disorder—Epirubicin—liver cancer	0.00129	0.00131	CcSEcCtD
Baclofen—Hyperhidrosis—Epirubicin—liver cancer	0.00128	0.0013	CcSEcCtD
Baclofen—Chest pain—Doxorubicin—liver cancer	0.00128	0.0013	CcSEcCtD
Baclofen—Myalgia—Doxorubicin—liver cancer	0.00128	0.0013	CcSEcCtD
Baclofen—Anxiety—Doxorubicin—liver cancer	0.00128	0.00129	CcSEcCtD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00127	0.00129	CcSEcCtD
Baclofen—Discomfort—Doxorubicin—liver cancer	0.00126	0.00128	CcSEcCtD
Baclofen—Anorexia—Epirubicin—liver cancer	0.00126	0.00128	CcSEcCtD
Baclofen—Ibuprofen—ALB—liver cancer	0.00126	0.273	CrCbGaD
Baclofen—Dry mouth—Doxorubicin—liver cancer	0.00125	0.00127	CcSEcCtD
Baclofen—Hypotension—Epirubicin—liver cancer	0.00124	0.00126	CcSEcCtD
Baclofen—Confusional state—Doxorubicin—liver cancer	0.00124	0.00126	CcSEcCtD
Baclofen—Oedema—Doxorubicin—liver cancer	0.00123	0.00125	CcSEcCtD
Baclofen—Infection—Doxorubicin—liver cancer	0.00122	0.00124	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Baclofen—Shock—Doxorubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Baclofen—Nervous system disorder—Doxorubicin—liver cancer	0.0012	0.00122	CcSEcCtD
Baclofen—Insomnia—Epirubicin—liver cancer	0.0012	0.00122	CcSEcCtD
Baclofen—Tachycardia—Doxorubicin—liver cancer	0.0012	0.00122	CcSEcCtD
Baclofen—Skin disorder—Doxorubicin—liver cancer	0.00119	0.00121	CcSEcCtD
Baclofen—Paraesthesia—Epirubicin—liver cancer	0.00119	0.00121	CcSEcCtD
Baclofen—Hyperhidrosis—Doxorubicin—liver cancer	0.00119	0.0012	CcSEcCtD
Baclofen—Dyspnoea—Epirubicin—liver cancer	0.00118	0.0012	CcSEcCtD
Baclofen—Somnolence—Epirubicin—liver cancer	0.00118	0.0012	CcSEcCtD
Baclofen—Anorexia—Doxorubicin—liver cancer	0.00117	0.00119	CcSEcCtD
Baclofen—Dyspepsia—Epirubicin—liver cancer	0.00117	0.00118	CcSEcCtD
Baclofen—Decreased appetite—Epirubicin—liver cancer	0.00115	0.00117	CcSEcCtD
Baclofen—Hypotension—Doxorubicin—liver cancer	0.00115	0.00116	CcSEcCtD
Baclofen—Gastrointestinal disorder—Epirubicin—liver cancer	0.00114	0.00116	CcSEcCtD
Baclofen—Fatigue—Epirubicin—liver cancer	0.00114	0.00116	CcSEcCtD
Baclofen—Pain—Epirubicin—liver cancer	0.00113	0.00115	CcSEcCtD
Baclofen—Constipation—Epirubicin—liver cancer	0.00113	0.00115	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00112	0.00113	CcSEcCtD
Baclofen—Insomnia—Doxorubicin—liver cancer	0.00111	0.00113	CcSEcCtD
Baclofen—Paraesthesia—Doxorubicin—liver cancer	0.0011	0.00112	CcSEcCtD
Baclofen—Dyspnoea—Doxorubicin—liver cancer	0.00109	0.00111	CcSEcCtD
Baclofen—Feeling abnormal—Epirubicin—liver cancer	0.00109	0.00111	CcSEcCtD
Baclofen—Somnolence—Doxorubicin—liver cancer	0.00109	0.00111	CcSEcCtD
Baclofen—Gastrointestinal pain—Epirubicin—liver cancer	0.00108	0.0011	CcSEcCtD
Baclofen—Dyspepsia—Doxorubicin—liver cancer	0.00108	0.0011	CcSEcCtD
Baclofen—Decreased appetite—Doxorubicin—liver cancer	0.00107	0.00108	CcSEcCtD
Baclofen—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00106	0.00108	CcSEcCtD
Baclofen—Fatigue—Doxorubicin—liver cancer	0.00106	0.00107	CcSEcCtD
Baclofen—Urticaria—Epirubicin—liver cancer	0.00105	0.00107	CcSEcCtD
Baclofen—Constipation—Doxorubicin—liver cancer	0.00105	0.00106	CcSEcCtD
Baclofen—Pain—Doxorubicin—liver cancer	0.00105	0.00106	CcSEcCtD
Baclofen—Abdominal pain—Epirubicin—liver cancer	0.00105	0.00106	CcSEcCtD
Baclofen—Body temperature increased—Epirubicin—liver cancer	0.00105	0.00106	CcSEcCtD
Baclofen—Feeling abnormal—Doxorubicin—liver cancer	0.00101	0.00103	CcSEcCtD
Baclofen—Gastrointestinal pain—Doxorubicin—liver cancer	0.001	0.00102	CcSEcCtD
Baclofen—Urticaria—Doxorubicin—liver cancer	0.000975	0.000989	CcSEcCtD
Baclofen—Abdominal pain—Doxorubicin—liver cancer	0.00097	0.000984	CcSEcCtD
Baclofen—Body temperature increased—Doxorubicin—liver cancer	0.00097	0.000984	CcSEcCtD
Baclofen—Asthenia—Epirubicin—liver cancer	0.000951	0.000966	CcSEcCtD
Baclofen—Pruritus—Epirubicin—liver cancer	0.000938	0.000952	CcSEcCtD
Baclofen—Diarrhoea—Epirubicin—liver cancer	0.000907	0.000921	CcSEcCtD
Baclofen—Asthenia—Doxorubicin—liver cancer	0.00088	0.000893	CcSEcCtD
Baclofen—Dizziness—Epirubicin—liver cancer	0.000877	0.00089	CcSEcCtD
Baclofen—Pruritus—Doxorubicin—liver cancer	0.000868	0.000881	CcSEcCtD
Baclofen—Vomiting—Epirubicin—liver cancer	0.000843	0.000856	CcSEcCtD
Baclofen—Diarrhoea—Doxorubicin—liver cancer	0.000839	0.000852	CcSEcCtD
Baclofen—Rash—Epirubicin—liver cancer	0.000836	0.000849	CcSEcCtD
Baclofen—Dermatitis—Epirubicin—liver cancer	0.000835	0.000848	CcSEcCtD
Baclofen—Headache—Epirubicin—liver cancer	0.000831	0.000843	CcSEcCtD
Baclofen—Dizziness—Doxorubicin—liver cancer	0.000811	0.000823	CcSEcCtD
Baclofen—Nausea—Epirubicin—liver cancer	0.000788	0.000799	CcSEcCtD
Baclofen—Vomiting—Doxorubicin—liver cancer	0.00078	0.000792	CcSEcCtD
Baclofen—Rash—Doxorubicin—liver cancer	0.000774	0.000785	CcSEcCtD
Baclofen—Dermatitis—Doxorubicin—liver cancer	0.000773	0.000784	CcSEcCtD
Baclofen—Headache—Doxorubicin—liver cancer	0.000769	0.00078	CcSEcCtD
Baclofen—Nausea—Doxorubicin—liver cancer	0.000729	0.00074	CcSEcCtD
Baclofen—GABBR2—Transmission across Chemical Synapses—GLUL—liver cancer	0.000511	0.0499	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—GLUL—liver cancer	0.000391	0.0383	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—CCR4—liver cancer	0.000347	0.0339	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—GLUL—liver cancer	0.000329	0.0322	CbGpPWpGaD
Baclofen—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.000301	0.0294	CbGpPWpGaD
Baclofen—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.000287	0.028	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—GLUL—liver cancer	0.000252	0.0247	CbGpPWpGaD
Baclofen—GABBR1—G alpha (i) signalling events—CCR4—liver cancer	0.000224	0.0219	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—CCR4—liver cancer	0.00021	0.0205	CbGpPWpGaD
Baclofen—GABBR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—liver cancer	0.000189	0.0185	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CHN2—liver cancer	0.00016	0.0156	CbGpPWpGaD
Baclofen—GABBR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—liver cancer	0.000158	0.0154	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IFT88—liver cancer	0.000146	0.0143	CbGpPWpGaD
Baclofen—GABBR2—Transmission across Chemical Synapses—BRAF—liver cancer	0.000142	0.0139	CbGpPWpGaD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000137	0.0134	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000136	0.0133	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000136	0.0133	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—CCR4—liver cancer	0.000135	0.0132	CbGpPWpGaD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00013	0.0127	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—TRIO—liver cancer	0.000124	0.0121	CbGpPWpGaD
Baclofen—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—liver cancer	0.000122	0.0119	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—CCR4—liver cancer	0.000119	0.0116	CbGpPWpGaD
Baclofen—GABBR2—Transmission across Chemical Synapses—RAF1—liver cancer	0.000118	0.0116	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—TRIO—liver cancer	0.000112	0.011	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—BRAF—liver cancer	0.000109	0.0106	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—CCR4—liver cancer	0.000108	0.0105	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CHN2—liver cancer	0.000103	0.0101	CbGpPWpGaD
Baclofen—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—liver cancer	0.000102	0.00993	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IFT88—liver cancer	9.43e-05	0.00922	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—BRAF—liver cancer	9.14e-05	0.00894	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—RAF1—liver cancer	9.08e-05	0.00888	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—SHC3—liver cancer	8.97e-05	0.00877	CbGpPWpGaD
Baclofen—GABBR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—liver cancer	8.68e-05	0.00849	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—F2—liver cancer	8.39e-05	0.00821	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—TRIO—liver cancer	7.98e-05	0.0078	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—CCR4—liver cancer	7.65e-05	0.00748	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—RAF1—liver cancer	7.63e-05	0.00747	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—TRIO—liver cancer	7.24e-05	0.00708	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—BRAF—liver cancer	7.01e-05	0.00685	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—FST—liver cancer	6.96e-05	0.00681	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—CCR4—liver cancer	6.95e-05	0.00679	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC11A2—liver cancer	6.94e-05	0.00679	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PRKCE—liver cancer	6.83e-05	0.00668	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TRIO—liver cancer	6.64e-05	0.00649	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC40A1—liver cancer	6.62e-05	0.00647	CbGpPWpGaD
Baclofen—GABBR2—Transmission across Chemical Synapses—HRAS—liver cancer	6.52e-05	0.00638	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CCR4—liver cancer	6.37e-05	0.00623	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ANXA2—liver cancer	6.35e-05	0.00621	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ATP7B—liver cancer	6.35e-05	0.00621	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PRKCE—liver cancer	6.21e-05	0.00607	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—CSF2—liver cancer	6.05e-05	0.00591	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—NR1H4—liver cancer	6e-05	0.00587	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—RAF1—liver cancer	5.85e-05	0.00572	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—SHC3—liver cancer	5.78e-05	0.00565	CbGpPWpGaD
Baclofen—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—liver cancer	5.59e-05	0.00547	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—CSF2—liver cancer	5.49e-05	0.00537	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—F2—liver cancer	5.41e-05	0.00529	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—ADAM17—liver cancer	5.03e-05	0.00492	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—HRAS—liver cancer	5e-05	0.00489	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—F2—liver cancer	4.74e-05	0.00464	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PSMA4—liver cancer	4.73e-05	0.00463	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PSMD10—liver cancer	4.73e-05	0.00463	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PIK3CG—liver cancer	4.54e-05	0.00444	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—FST—liver cancer	4.49e-05	0.00439	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PRKCE—liver cancer	4.4e-05	0.00431	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—F2—liver cancer	4.31e-05	0.00421	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TRIO—liver cancer	4.28e-05	0.00419	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—HRAS—liver cancer	4.2e-05	0.00411	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PIK3CG—liver cancer	4.12e-05	0.00403	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CCR4—liver cancer	4.1e-05	0.00401	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PRKCE—liver cancer	4e-05	0.00391	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PIK3CD—liver cancer	3.99e-05	0.0039	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—CSF2—liver cancer	3.9e-05	0.00381	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PRKCE—liver cancer	3.67e-05	0.00359	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PIK3CD—liver cancer	3.62e-05	0.00354	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—CSF2—liver cancer	3.54e-05	0.00346	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PIK3CB—liver cancer	3.48e-05	0.0034	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IGF2—liver cancer	3.47e-05	0.0034	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CSF2—liver cancer	3.24e-05	0.00317	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ADAM17—liver cancer	3.24e-05	0.00317	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—RAF1—liver cancer	3.24e-05	0.00316	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—HRAS—liver cancer	3.22e-05	0.00315	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—H2AFX—liver cancer	3.2e-05	0.00313	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—IL2—liver cancer	3.19e-05	0.00312	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PIK3CB—liver cancer	3.16e-05	0.00309	CbGpPWpGaD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—ALB—liver cancer	3.14e-05	0.00307	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—CYCS—liver cancer	3.06e-05	0.00299	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—F2—liver cancer	3.06e-05	0.00299	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PSMD10—liver cancer	3.05e-05	0.00298	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PSMA4—liver cancer	3.05e-05	0.00298	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PIK3CG—liver cancer	2.93e-05	0.00286	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—IL2—liver cancer	2.9e-05	0.00284	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TERT—liver cancer	2.89e-05	0.00283	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—F2—liver cancer	2.78e-05	0.00271	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—HMOX1—liver cancer	2.66e-05	0.0026	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PIK3CG—liver cancer	2.66e-05	0.0026	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—KDR—liver cancer	2.64e-05	0.00259	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MAPK14—liver cancer	2.63e-05	0.00257	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—ESR1—liver cancer	2.58e-05	0.00252	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PIK3CD—liver cancer	2.57e-05	0.00252	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—F2—liver cancer	2.54e-05	0.00249	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—APC—liver cancer	2.44e-05	0.00238	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PIK3CG—liver cancer	2.44e-05	0.00238	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PRKCE—liver cancer	2.36e-05	0.00231	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PIK3CD—liver cancer	2.34e-05	0.00228	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—BRAF—liver cancer	2.29e-05	0.00224	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PIK3CB—liver cancer	2.24e-05	0.00219	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IGF2—liver cancer	2.24e-05	0.00219	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—PPARA—liver cancer	2.15e-05	0.0021	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PIK3CD—liver cancer	2.14e-05	0.00209	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PIK3CA—liver cancer	2.12e-05	0.00207	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—SERPINE1—liver cancer	2.12e-05	0.00207	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—KRAS—liver cancer	2.1e-05	0.00205	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CSF2—liver cancer	2.09e-05	0.00204	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—RAF1—liver cancer	2.09e-05	0.00204	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—H2AFX—liver cancer	2.06e-05	0.00201	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—IL2—liver cancer	2.06e-05	0.00201	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PIK3CB—liver cancer	2.04e-05	0.00199	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PIK3CA—liver cancer	1.93e-05	0.00188	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—RAF1—liver cancer	1.91e-05	0.00187	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—IL2—liver cancer	1.87e-05	0.00183	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MTOR—liver cancer	1.87e-05	0.00183	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PIK3CB—liver cancer	1.87e-05	0.00183	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TERT—liver cancer	1.86e-05	0.00182	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—HRAS—liver cancer	1.78e-05	0.00174	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CDKN1B—liver cancer	1.75e-05	0.00171	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—AKT1—liver cancer	1.73e-05	0.00169	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CASP3—liver cancer	1.72e-05	0.00168	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IL2—liver cancer	1.71e-05	0.00168	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—IL6—liver cancer	1.71e-05	0.00167	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—KDR—liver cancer	1.7e-05	0.00167	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MAPK14—liver cancer	1.69e-05	0.00166	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CCND1—liver cancer	1.67e-05	0.00163	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—JUN—liver cancer	1.67e-05	0.00163	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ESR1—liver cancer	1.66e-05	0.00162	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CTNNB1—liver cancer	1.65e-05	0.00162	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—F2—liver cancer	1.64e-05	0.0016	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MMP9—liver cancer	1.62e-05	0.00159	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CDKN1A—liver cancer	1.62e-05	0.00158	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ALB—liver cancer	1.6e-05	0.00156	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MAPK8—liver cancer	1.58e-05	0.00154	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—AKT1—liver cancer	1.57e-05	0.00154	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—APC—liver cancer	1.57e-05	0.00153	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PIK3CG—liver cancer	1.57e-05	0.00153	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—BRAF—liver cancer	1.48e-05	0.00144	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—VEGFA—liver cancer	1.46e-05	0.00142	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—RAF1—liver cancer	1.44e-05	0.00141	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—STAT3—liver cancer	1.44e-05	0.00141	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PIK3CD—liver cancer	1.38e-05	0.00135	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PIK3CA—liver cancer	1.37e-05	0.00134	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—SERPINE1—liver cancer	1.36e-05	0.00133	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—KRAS—liver cancer	1.35e-05	0.00132	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MYC—liver cancer	1.34e-05	0.00131	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TGFB1—liver cancer	1.34e-05	0.00131	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PIK3CA—liver cancer	1.24e-05	0.00121	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—KRAS—liver cancer	1.24e-05	0.00121	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—RAF1—liver cancer	1.23e-05	0.0012	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PIK3CB—liver cancer	1.2e-05	0.00118	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MTOR—liver cancer	1.2e-05	0.00118	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—HRAS—liver cancer	1.15e-05	0.00112	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PIK3CA—liver cancer	1.14e-05	0.00111	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CDKN1B—liver cancer	1.13e-05	0.0011	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—AKT1—liver cancer	1.12e-05	0.00109	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CASP3—liver cancer	1.11e-05	0.00108	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IL2—liver cancer	1.1e-05	0.00108	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TP53—liver cancer	1.1e-05	0.00108	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—IL6—liver cancer	1.1e-05	0.00107	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CCND1—liver cancer	1.08e-05	0.00105	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—JUN—liver cancer	1.07e-05	0.00105	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CTNNB1—liver cancer	1.07e-05	0.00104	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—HRAS—liver cancer	1.05e-05	0.00103	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MMP9—liver cancer	1.05e-05	0.00102	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CDKN1A—liver cancer	1.04e-05	0.00102	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MAPK8—liver cancer	1.02e-05	0.000994	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—AKT1—liver cancer	1.01e-05	0.000991	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IL6—liver cancer	1.01e-05	0.000985	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—VEGFA—liver cancer	9.39e-06	0.000918	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—STAT3—liver cancer	9.29e-06	0.000909	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—AKT1—liver cancer	9.29e-06	0.000909	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MYC—liver cancer	8.64e-06	0.000845	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TGFB1—liver cancer	8.61e-06	0.000842	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—KRAS—liver cancer	7.98e-06	0.00078	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PIK3CA—liver cancer	7.33e-06	0.000717	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TP53—liver cancer	7.09e-06	0.000694	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—HRAS—liver cancer	6.78e-06	0.000663	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IL6—liver cancer	6.49e-06	0.000635	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—AKT1—liver cancer	5.99e-06	0.000586	CbGpPWpGaD
